Rapid Influenza Diagnostic Tests Market - Growth Prospects and Forecast by Technavio

Technavio has published a new report on the global rapid influenza diagnostic tests market from 2017-2021. (Graphic: Business Wire)

LONDON--()--According to the latest market study released by Technavio, the global rapid influenza diagnostic tests (RIDTs) market is expected to grow at a CAGR of more than 9% during the forecast period.

This research report titled ‘Global Rapid Influenza Diagnostic Tests Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This report also includes an up to date analysis and forecasts for various market segments and all geographical regions.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

The market research analysis categorizes the global rapid influenza diagnostic tests market into three major end-user segments. They are:

  • Hospitals and diagnostic laboratories
  • Academic and research centers
  • Homecare

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Hospitals and diagnostic laboratories

According to the CDC data, approximately 31.4 million outpatient visits and 200,000 hospitalizations happen every year after being infected by influenza, and an estimated 20 million rapid tests have been performed in the US. These statistics are highly significant when it comes to the growing demand for rapid diagnostic kits in hospitals.

This segment accounts for the largest share of the global RIDTs market due to the presence of various levels of healthcare specialties such as primary care, specialty care, and super-specialty care. RIDT kits provide an immediate solution in the public care domain where sophisticated diagnostic instruments are not easily accessible. For instance, in the case of epidemics, a large pool of patients visit hospitals and diagnostic laboratories to get tested.

According to Neha Noopur, a lead analyst at Technavio for in-vitro diagnostics research, “Hospitals are the first choice for treatment, diagnosis, and surgical interventions for individuals suffering from critical medical conditions, severe pain, or infection. Availability of skilled professionals with knowledge and expertise in treating and diagnosing such conditions attracts patient attention towards hospital care, which augurs well for the growth of the RIDT market.”

Academic and research centers

Academic and research institutes are focused on developing innovative point-of-care (POC) influenza diagnostic test kits, due to growing demand for POC testing (POCT). These centers are striving hard to develop technologically advanced RIDTs that support physicians with data related to diagnosis and prognosis. These centers provide various diagnostic solutions in the clinical and industrial area to bring improved diagnostic results for screening and monitoring influenza A and influenza B and are also used to detect microorganisms in the reagent used in testing influenza virus.

Many academic centers study the feasibility of these diagnostic test kits and are active end-users of RIDT kits. They are focused on identifying limitations associated with the rapid tests. Also, they offer different services to the manufacturers to improve their production capability and adoption rate in primary care. For instance, the National Institute for Health Research Diagnostic Evidence Co-operative, Oxford (NIHR DEC Oxford) takes up projects to evaluate in-vitro diagnostic tests such as RIDTs.

Homecare

Various prominent healthcare organizations provide homecare facilities for individuals who are old, critically ill, or disabled due to which they cannot move to hospitals or diagnostic laboratories for diagnosis of influenza virus.

The RIDT kit is developed in a way that a novice can easily use it after receiving minimal training. It provides results very quickly, thus making it possible to commence treatment immediately. Moreover, it enables other people in the family and neighborhood to take precautions as the influenza virus is highly contagious.

“The increasing awareness about RIDTs and POCT contributes to the significant share acquired by the homecare segment. Moreover, factors such as increasing life expectancy, leading to increased number of elderly population, intensifies the demand for such diagnostic test kits for homecare services. Also, the increasing penetration of homecare agencies, long-term care programs, and home services is expected to fuel the growth of the global RIDTs market,” says Neha.

The top vendors highlighted by Technavio’s market research analysts in this report are:

  • Alere
  • BD
  • Quidel

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

According to the market study released by Technavio, the global rapid influenza diagnostic tests market is set to post a CAGR of over 9% until 2021.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com